Evolocumab
CAS No. 1256937-27-5
Evolocumab( —— )
Catalog No. M22151 CAS No. 1256937-27-5
Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 851 | In Stock |
|
| 10MG | 1152 | In Stock |
|
| 25MG | 1782 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEvolocumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionEvolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
-
DescriptionEvolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetPCSK9
-
RecptorPCSK9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1256937-27-5
-
Formula Weight144 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sreeneeranj Kasichayanula, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018; 57(7): 769–779.
molnova catalog
related products
-
Alirocumab
Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture.
-
PF-06815345
PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay.
-
O-304
O-304 is a small molecule AMPK activator and PCSK9 modulator, reduces extracellular and secreted PCSK9 levels in human liver cells and reduces PCSK9 plasma levels and total cholesterol levels in obese rats.
Cart
sales@molnova.com